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In silico (computed) modelling of doses  
and dosing regimens associated with 
morphine levels above international  
legal driving limits
Jason W Boland1 , Miriam Johnson1 , Diana Ferreira2  
and David J Berry3
Abstract
Background: Morphine can cause central nervous system side effects which impair driving skills. The legal blood morphine 
concentration limit for driving is 20 µg/L in France/Poland/Netherlands and 80 µg/L in England/Wales. There is no guidance as to the 
morphine dose leading to this concentration.
Aim: The in silico (computed) relationship of oral morphine dose and plasma concentration was modelled to provide dose estimates 
for a morphine plasma concentration above 20 and 80 µg/L in different patient groups.
Design: A dose–concentration model for different genders, ages and oral morphine formulations, validated against clinical 
pharmacokinetic data, was generated using Simcyp®, a population-based pharmacokinetic simulator.
Setting/participants: Healthy Northern European population parameters were used with age, gender and renal function being 
varied in the different simulation groups. In total, 36,000 simulated human subjects (100 per modelled group of different ages and 
gender) received repeated simulated morphine dosing with modified-release or immediate-release formulations.
Results: Older age, women, modified-release formulation and worse renal function were associated with higher plasma concentrations. 
Across all groups, morphine doses below 20 mg/day were unlikely to result in a morphine plasma concentration above 20 µg/L; this 
was 80 mg/day with the 80 µg/L limit.
Conclusion: This novel study provides predictions of the in silico (computed) dose–concentration relationship for international 
application. Individualised morphine prescribing decisions by clinicians must be informed by clinical judgement considering the individual 
patient’s level of impairment and insight irrespective of the blood morphine concentration as people who have impaired driving will be 
breaking the law. Taking into account expected morphine concentrations enables improved individualised decision making.
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What is already known on the topic?
•• Morphine can cause central nervous system side effects which impair driving.
•• The blood morphine concentration driving legal limit is 20 µg/L in France/Poland/Netherlands and 80 µg/L in England/
Wales.
•• There is no dose–concentration guidance as to what morphine dose would lead to these concentrations.
What this paper adds?
•• For the same oral morphine dose, older age, women, modified-release formulation and worse renal function are associ-
ated with higher morphine plasma concentrations.
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•• With normal renal function,<20 mg/day morphine is unlikely to result in a morphine plasma concentration above 20 µg/L; 
this is <80 mg/day morphine for the 20 µg/L limit.
Implications for practice, theory or policy
•• The morphine dose–concentration relationship helps inform individualised prescribing decisions by clinicians for people 
needing morphine.
•• Clinical judgement considering the individual patient’s level of impairment and insight for any plasma concentration is 
needed.
Introduction
Morphine is commonly prescribed for pain management 
and can cause central nervous system harms such as cogni-
tive and psychomotor impairment which can have a nega-
tive impact on driving skills.1,2 An offence of driving with 
certain controlled drugs above specified blood limits came 
into force in England and Wales in March 2015.3,4 This 
includes a 80-µg/L morphine limit at the time of testing.3,4 
It gives police powers to arrest and test people suspected 
of driving with higher than specified blood levels of cer-
tain controlled drugs. The 80 µg/L limit was established 
after taking into account epidemiological and experimen-
tal data of blood morphine concentrations of individuals 
and impaired driving.5 However, the legal blood concen-
tration of morphine varies across European countries from 
9 µg/L (Norway), to 20 µg/L (France, Poland, Netherlands) 
to 80 µg/L (England/Wales).5,6 In the United States, driving 
on therapeutic opioids varies between states.7 Arizona, 
Indiana, Iowa, Minnesota and North Carolina have statu-
ary defences for drivers taking prescription opioids. In 
Maine, South Dakota and Wyoming, driving while taking 
prescription drugs known to impair driving is prohibited, 
even if driving is not affected.7 In Australia, people taking 
opioids are not allowed to drive if their driving is impaired, 
irrespective of blood levels. For unimpaired drivers, in 
Australia and New Zealand, no blood concentration cut-
off applies.8,9 This heterogeneity in laws within and 
between countries illustrates that a concentration–impair-
ment relationship is not established. National and interna-
tional medical recommendations also reflect this 
uncertainty. In a UK National Health Service document, 
oral morphine equivalent doses above 220 mg/day were 
considered probably not safe to drive.10 The Royal College 
of Anaesthetists states that doses around 200 mg/day could 
be as dangerous as having borderline illegal driving blood 
alcohol levels.11 The American College of Occupational 
and Environmental Medicine states that acute and chronic 
opioid use is not recommended for patients who operate 
motor vehicles.12
Anyone driving in England and Wales with blood con-
centrations above 80 µg/L will be breaking the law, whether 
their driving was impaired or not. However, people taking 
morphine for medical reasons may have a statutory ‘medical 
defence’ if they have blood concentrations greater than the 
legal limit.3,4 For this defence to be valid, their driving must 
be unimpaired, the drug must be prescribed, supplied/sold to 
treat a medical problem and taken in accordance with pre-
scriber instructions (or the medicine information leaflet). 
Written evidence may be required. Despite the clear guid-
ance on blood concentrations, there is no guidance relating 
to the dose which would equate to being over the specified 
limits.3 A Swedish study of 2029 apprehended drivers 
showed that those individuals who had morphine detected 
in their blood had a mean morphine concentration of 46 µg/L 
(2.5 and 97.5 percentiles: 6 and 210 µg/L).13 This indicates 
that a proportion of apprehended drivers had morphine con-
centrations above 80 µg/L and most above 20 µg/L. 
Furthermore, drug-impaired driving does not necessarily 
relate to plasma concentration of morphine.13
In clinical practice, the dose of morphine which approx-
imates to morphine blood concentrations of 20 and 80 µg/L 
is not known. This study aimed to model the relationship 
between oral morphine daily dose and plasma concentra-
tion for which the driving laws apply to help inform per-
sonalised patient decisions. In silico (computed) 
pharmacokinetic modelling was used to account for inter-
individual variables across different ages and genders, and 
to detect differences between oral morphine preparations.
Methods
In silico physiology-based pharmacokinetic modelling 
was used to assess the plasma concentrations which relate 
to oral doses of immediate and modified-release mor-
phine (MST Continus®) in order to estimate the daily 
dose of morphine which is likely to produce a plasma 
concentration of 20 and 80 µg/L. This was modelled in 
men and women across a range of ages. A number of soft-
ware and models are available, offering different focal 
strengths.14–17
Calculations were undertaken using Simcyp® Population-
Based Simulator software (version 14; Certara™ , New Jersey, 
USA). This software simulates absorption and metabolism in 
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a physiology-based modelling platform, delivering a range of 
dose–plasma concentrations across a diverse population.18 In 
silico characterises biological experiments carried out entirely 
on a computer, applying algorithms or computer simulations 
to model biological processes. These in silico techniques are 
widely used in such a way to model representative data from a 
large number of potential subjects.18,19 To adequately predict 
in vivo behaviours from in vitro data, the models use informa-
tion on the human body for each ‘test’ subject, the physical 
chemistry of the drug molecule and the conditions of its use 
(dose and dosing schedule). Physical chemistry of the drug 
and dosing schedule were implemented based on information 
from the Royal Society of Chemistry’s ChemSpider, Drug 
Bank and dosing through the British National Formulary.20,21 
Distribution was calculated using the minimal physiologically 
based pharmacokinetic (PBPK) model option with volume of 
distribution included as a user input of 2.9 L/kg with a 27% 
coefficient of variance.22 To enable calculation of individual 
patient variability factors, multivariate models are used to 
ensure valid predictions of the key processes such as absorp-
tion and metabolism.23–25 The covariates for these processes 
have been previously described.18,26–28 In the gastrointestinal 
tract, Simcyp’s Advanced Dissolution Adsorption and 
Metabolism (ADAM) multi-compartmental models are used 
to represent the physiological state.29,30 These models use mul-
tiple mathematical ‘compartments’ (from stomach to anus) 
which contain a volume and flow rate, representing the physi-
ological state. Within each of these compartments, release of 
the drug, interaction with the gut wall (degradation and metab-
olism), absorption (passive and active) and first-pass liver 
metabolism are considered. The model accounts for changes 
in liver function associated with ageing, based on the microso-
mal protein per gram of liver in ageing samples.31 Average 
renal function for each age group is calculated using the 
Cockcroft and Gault equation.32
The ‘healthy Northern European population’ was used 
for this study, with all model values retained except for 
age, gender and renal function. These values were altered 
to ascertain the dose–pharmacokinetic relationships for 
different groups.
The pharmacokinetic model for morphine was vali-
dated in two stages. First, parameters were developed to 
match maximum concentration (Cmax), time to achieve 
maximum concentration (Tmax), area under the curve 
(AUC) and plasma/time shape parameters, with clearance 
and volume of distribution used from the mean of reported 
data.22,33–36 Second, the predicted and measured plasma 
concentrations across the dose range at steady state were 
compared.35–37 This represented the best available popula-
tion data for the dosing of morphine with slight over pre-
diction being built into the model to ensure conservative 
clinical application (Figure 1).
Dosing intervals were selected due to clinical relevance, 
with a 12-h interval used for modified-release dosing and 
a 6-h interval for immediate-release dosing. Although 
immediate-release dosing can occur at 4-hourly intervals, 
often the dose is taken less than six times a day. 
Furthermore, the same dose at 4- and 6-hourly dosing 
intervals resulted in comparable mean maximum plasma 
concentrations at steady state, with the 6-hourly dose lead-
ing to an increased chance of being above 80 µg/L and thus 
would provide the more conservative guidance (Figure 2).
Age, gender and renal function parameters were altered in 
the model to explore the dose–pharmacokinetic relationships 
for different groups of people. For both men and women, age 
ranges of 18–90 years were used, divided into 18–40 and 
then in 10-year intervals. The effect of renal failure on dose–
concentration relationship was evaluated by adjusting renal 
function parameters in line with the National Kidney 
Foundation classification of glomerular filtration rate (GFR) 
for mild (70 mL/min/1.73 m2), moderate (50 mL/min/1.73 m2) 
and severe (20 mL/min/1.73 m2) renal failure.38
Sampling intervals were 15 min for the immediate-
release preparation model and 40 min for the modified-
release model, for at least 7 days. Prediction of the amount 
of time a person is likely to be over the limit is based on the 
number of sampled points within a simulated 24-h period 
that were over 80 µg/L (Figure 2). All data points above 
80 µg/L (Figure 2) would be considered as time over the 
legal limit. Such data would not be captured from the mean 
plasma concentrations (Figure 2), which are below the 
legal limit and if used alone would wrongly classify the 
patient as under the legal limit at this dose.
Plasma concentration over time was modelled for mor-
phine doses between 5–200 mg twice-daily in 5 mg incre-
ments to 100 mg, 25 mg intervals thereafter; and 10–200 mg 
four-times daily in 10 mg intervals, for modified and 
immediate-release oral preparations, respectively. Each dose 
of each formulation was simulated on 100 individuals for 
at least 7 days to ensure steady state was reached. Mean 
data from the 100 individuals were used to determine the 
dose to plasma concentration relationship. Individual data-
sets can be found in the online supplement. These data 
were then analysed to determine the number of hours 
which those individuals with the highest Cmax response 
were over the legal limit (20 or 80 µg/L) for a given dose. 
This was achieved by use of the 95th percentile data from 
each sub-population, with these data reported in Figures 3, 
4 and Supplementary Figures 1 and 2 – as the aim of this 
work was to determine doses conveying the highest risk of 
a patient being above the legal limit.
The law states the legal morphine concentration in 
blood. Morphine levels between whole blood and plasma 
have previously been reported to correlate in a linear fash-
ion with a relationship close to 1.02.39
Results
In silico modelling for 100 ‘men’ and 100 ‘women’ for each 
age range and dose gives a mean of the oral morphine dose 
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concentration relationship. The dose precision within the 
data is limited to the order of 10–20 mg dosing intervals, as 
per the axis of the charts. From this, it is possible to deter-
mine, in each population, the dose which equates to a mor-
phine plasma concentration (Figure 3 and Supplementary 
Figure 1).
The dose which equates to the legal morphine plasma 
concentration in France, Poland, Netherlands (20 µg/L) 
and England/Wales (80 µg/L) can be determined (Figure 
3 and Supplementary Figure 1). The morphine plasma 
concentration has also been represented by the time a 
person is likely to be over 80 µg/L (Figure 4 and 
Supplementary Figure 2). This is shown at steady state 
for people of different ages, genders, morphine formula-
tions (assuming normal renal and hepatic function for 
that age/gender) and renal failure (Figure 4 and 
Supplementary Figure 2).
Mild renal failure did not significantly affect morphine 
concentrations, with reduced hepatocyte concentrations 
showing a greater impact – included within modelling of 
Figure 1. Model validation via comparison of mean data from clinical trials35–37 of (a) 20 mg immediate-release oral formulation and 
the in silico model in healthy diverse individuals and (b) 30 mg modified-release morphine tablets and the in silico model in healthy 
diverse individuals. Error bars show 10% standard error in the model and studied variance within clinical subjects in the trial data.
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the older age groups. As morphine is renally excreted, 
increasing severity of renal failure increased the duration 
of the morphine plasma concentration being above 20 or 
80 µg/L; this was especially so for immediate-release mor-
phine (Supplementary Figures 1 and 2).
Older age, women and poor renal function were associ-
ated with higher plasma concentrations (Figures 3 and 4; 
Table 1).
Discussion
Using in silico modelling, this study estimates a dose–
plasma concentration relationship in the context of the 
legal morphine limit, taking into account gender, age, renal 
function and morphine preparation. Table 1 presents a clin-
ical guide to estimate the dose–plasma concentration like-
lihood in terms of exceeding the England/Wales legal 
blood morphine driving limit of 80 and 20 µg/L in France, 
Poland and Netherlands. Older age (especially above 
70 years of age), women, modified-release morphine for-
mulation and worsening renal function were associated 
with higher plasma concentrations. These modelling data 
give an approximation of the morphine dose, across a 
range of situations, which would likely lead to a morphine 
plasma concentration of ⩾20 or 80 µg/L. The model does 
not consider specific diseases, how other factors and other 
drugs affect metabolism and cognition and how cognition 
itself relates to safe driving. This must be determined by 
the clinician and patient, including assessment of the 
patient’s own perspective of their cognitive performance 
and ability to drive at that instance.40
In patients with cancer pain, daily morphine doses in 
studies were mostly between 100 and 250 mg but ranged 
from 25 to 2000 mg.41 This indicates that many patients 
will be on morphine doses that, according to our model, 
could lead to a morphine plasma concentration above 20 
and even 80 µg/L. This is also the case for patients on opi-
oids for non-cancer pain, where 19% (n = 455) were on 
over 200 mg morphine equivalent/day,42 and opioid-
dependent patients being treated with morphine (n = 211), 
mean daily dose 791 ± 233 mg/day.43
The model shows that compared with 12-hourly modi-
fied-release morphine, higher daily doses of 6-hourly imme-
diate-release morphine are needed to achieve a morphine 
plasma concentration above 20 or 80 µg/L. This is because 
time over 20 and 80 µg/L is the main outcome, rather than the 
mean plasma concentration (which would not detect people 
at risk of being above 20 or 80 µg/L; Figure 2). Due to 
absorption differences, immediate-release morphine formu-
lations produce a higher Cmax, for a shorter period compared 
to equivalent doses of modified release. Although equivalent 
doses of modified-release morphine were associated with 
higher plasma concentrations, the concentration oscillations 
associated with repeated immediate-release administration 
Figure 2. Comparison of 240 mg daily dosing and its effect on time spent over the legal limit for 40 mg 4-hourly, 60 mg 6-hourly, 
immediate-release and 120 mg 12-hourly modified-release oral morphine in the 70- to 80-year-old female group, also displayed is 
the 80 µg/L England and Wales legal limit and mean plasma concentration.
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might have a detrimental effect on skills required for driv-
ing.44–46 The modified-release model was for MST Continus.
In the model, older people, particularly above 70 years 
old, have a higher morphine plasma concentration for a 
given morphine dose. This is because as age increases, 
renal and hepatic function deteriorates (although this 
may remain within the normal range for the age group) 
and muscle mass reduces. In the renal failure model, 
estimated GFR is decreased, increasing the plasma con-
centration of morphine. Although mild renal failure did 
not affect morphine concentrations, which is expected 
when considering morphine concentrations alone (i.e. 
not the metabolites due to its high water solubility.47 Due 
to the higher Cmax in modified-release preparations, the 
time above 80 µg/L is differently affected in modified-
release versus immediate-release preparations, although 
the proportional change is comparable for both prepara-
tion types. Women have a higher plasma concentration 
from a given dose compared to men due to proportion-
ally smaller bodies and associated organs used for 
metabolism and clearance of morphine (liver and 
kidneys).48
As pain might have a detrimental effect on driving,49,50 
it is important this is well managed and appropriate anal-
gesics are not stopped.
Strengths and limitations
This study used in silico techniques to correlate morphine 
dose to plasma concentration. Age, gender, renal function 
and morphine formulation have been modelled for. The 
strength of PBPK modelling is that 36,000 simulated 
subjects at different ages and gender were simulated to 
receive repeated morphine dosing with both modified-
release and immediate-release morphine formulations. 
The model has been shown to correlate with dose–con-
centration responses to in vivo study data.34,35,51–54 
However, our model predicts higher plasma concentra-
tions for a given morphine dose compared to in vivo data 
due to cautious model preparation to ensure that doses 
Figure 3. The maximum morphine concentration (Cmax) is related to the daily morphine dose, in men (top) and women (bottom) 
divided into ages, taking different doses of immediate-release (left) and modified-release (right) morphine. The red lines represent 
the legal plasma levels in France, Poland, Netherlands (20 µg/L) and England/Wales (80 µg/L). Due to population variance, accuracy 
is only within the 10–20 mg dosage range presented on the scale bars; the 95th percentile data are presented here as a worst case 
scenario.
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were not under predicting; this can be seen in the com-
parative data (Figure 1).35–37
Our model used one immediate-release and one modi-
fied-release formulation, based on collated published phar-
macokinetic data.22,33–36 Clinically differing formulations 
and circumstances will lead to differing absorption kinetics 
between formulations, potentially leading to differing dose–
concentration relationships in individuals. These findings 
offer an insight into the changing pharmacokinetic relation-
ship with age and the effect an average dose will have and 
will help guide the clinician. People taking as required 
immediate-release morphine might do so at different dosing 
intervals. Some individuals might take 4 hourly doses 
instead. In practice, most patients do not take a dose over-
night (e.g. 2:00 a.m.), and thus, the average dose interval is 
nearer 6 h than 4 h. We modelled morphine 6 hourly to clini-
cal applicability within the confines of the software (as a 
dose gap cannot be added, for sleep/dose omission, etc.). 
Furthermore, during repeated administration, the individual 
morphine dose leading to a plasma concentration over 20 or 
80 µg/L was effectively the same for 4 and 6 hourly dosing.
This study cannot account for all the variabilities 
between individuals. With 100 ‘people’ per modelled phar-
macokinetic trial group, the results should be representative 
for northern European populations. A degree of variability 
around the ‘normal’ state has been included within the 
model, but this does not account for extreme variability. 
Extremes of body mass index (BMI), eating, drinking, drug 
interactions, and effects from the underlying disease/other 
co-morbidities have not been included in this model. These 
individual variables could potentially alter the pharmacoki-
netics and metabolism of morphine.3,55 The models suggest 
that cytochrome P450 enzyme inhibitors (inhibitors of 
hepatic clearance) would have a profound effect. As the 
active metabolites of morphine (e.g. morphine-6-glucuron-
ide) are not included in the new law, they have not been 
modelled for, although morphine-6-glucuronide can have 
an impact on driving performance.56 Multiple drugs have 
not been accounted for in the current study, although mor-
phine is often used with other medications.6,57–59 The clini-
cian must take all these factors into account.5
Future research
Data using driving simulators and on-the-road assessments 
of the effects of stable morphine at different dose ranges, 
as well as opioid initiation and titration are needed. 
Although the law does not include morphine metabolites, 
they might influence cognition and driving. Future work 
should ascertain the concentrations of morphine metabo-
lites and their relationship with cognitive, psychomotor 
function and driving impairment in different patient 
groups. The effects of immediate-release morphine taken 
‘as-required’ in addition to regular modified-release mor-
phine on morphine plasma concentrations are needed.
Clinical implications
This in silico modelling study evaluated the relationship 
between morphine dose and plasma concentration. This 
will help guide clinicians to know whether a patient is 
likely to have a plasma concentration above 20 or 80 µg/L 
(the legal driving limit), but this does not inform the risk of 
impaired driving for any individual for any plasma con-
centration. As there will be inter-individual variability, it is 
important that these data are used to guide personalised 
patient decisions, not make them.
Older age, women, modified-release formulation and 
worse renal function were associated with higher plasma 
concentrations. In general, across all studied groups, mor-
phine doses below 120 mg/day were unlikely to result in a 
morphine plasma concentration above 80 µg/L. This was 
much lower at 30 mg/day for the 20 µg/L limit in France, 
Poland and Netherlands. An immediate-release morphine 
dose taken alongside modified-release morphine would 
lead to a higher plasma concentration.
Table 1. Estimated daily morphine doses below the legal driving limits.
Legal limit 20 µg/L 80 µg/L
Total daily dose (mg)
(given as QDS IR)
Total daily dose (mg)
(given as BD MR)
Total daily dose (mg)
(given as QDS IR)
Total daily dose (mg)
(given as BD MR)
Age (years) Men Women Men Women Men Women Men Women
18–40 55 40 40 35 220 170 155 130
40–50 50 40 35 30 200 160 140 115
50–60 50 40 35 30 190 150 140 110
60–70 45 35 35 25 180 140 130 105
70–80 40 30 30 25 150 120 115 90
80–90 30 25 25 20 130 100 100 80
Dose below which the estimated time over the legal limit in France, Poland, Netherlands (20 µg/L) and England/Wales (80 µg/L) is zero – by gender 
and age and preparation (MR: modified release; IR: immediate release) with normal renal function. BD is twice-daily, QDS is four-times daily.
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The prescribing clinician must retain clinical judgement 
for each patient and advise to restrict driving until they know 
the effect of morphine on their driving ability. Both the legal 
limit and the actual effect on driving as well as patients’ own 
perspective of their cognitive performance need to be taken 
into consideration as people with impaired driving will be 
breaking the law irrespective of blood concentration.
Conclusion
In silico modelling of the dose–concentration relationship 
helps inform which patients are likely to have higher 
plasma concentrations after taking oral morphine. This 
information can help clinicians to make individualised 
prescribing decisions and provide advice on driving. 
Clinical judgement taking into account the individual 
patient’s level of impairment and insight is needed along-
side understanding the dose–concentration relationship, as 
people who have impaired driving will be breaking the law 
irrespective of their morphine plasma concentration.
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